Vir Biotechnology's Stock Surges on Strategic Partnership with Astellas Pharma
Vir Biotechnology's shares jumped 58% after announcing a strategic partnership with Astellas Pharma to develop VIR-5500, a prostate cancer drug. This collaboration includes significant milestone payments, positively affecting investor sentiment amid strong quarterly performance.
View signal analysis